Skip to main navigation Skip to search Skip to main content

Idiopathic short stature: Management and growth hormone treatment

  • J. M. Wit
  • , E. O. Reiter
  • , J. L. Ross
  • , P. H. Saenger
  • , M. O. Savage
  • , A. D. Rogol
  • , P. Cohen
  • Leiden University
  • Tufts University
  • Thomas Jefferson University
  • Alfred I. duPont Hospital for Children
  • Yeshiva University
  • Queen Mary University of London
  • University of Virginia
  • University of California at Los Angeles

Research output: Contribution to journalReview articlepeer-review

70 Scopus citations

Abstract

In the management of ISS auxological, biochemical, psychosocial and ethical elements have to be considered. In boys with constitutional delay of growth and puberty androgens are effective in increasing height and sexual characteristics, but adult height is unchanged. GH therapy is efficacious in increasing height velocity and adult height, but the inter-individual variation is considerable. The effect on psychosocial status is uncertain. Factors affecting final height gain include GH dose, height deficit in comparison to midparental height, age and first year height velocity. In case of a low predicted adult height at the onset of puberty, addition of a GnRH analogue can be considered. Although GH therapy appears safe, long-term monitoring is recommended.

Original languageEnglish
Pages (from-to)111-135
Number of pages25
JournalGrowth Hormone and IGF Research
Volume18
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Keywords

  • Aromatase inhibitors
  • Cost-benefit ratio
  • GnRH analogues
  • Growth
  • Growth hormone therapy
  • IGF-I
  • Idiopathic short stature
  • Monitoring
  • Oxandrolone
  • Quality of life
  • Sex steroids

Fingerprint

Dive into the research topics of 'Idiopathic short stature: Management and growth hormone treatment'. Together they form a unique fingerprint.

Cite this